<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882230</url>
  </required_header>
  <id_info>
    <org_study_id>AMR_2016_13</org_study_id>
    <nct_id>NCT02882230</nct_id>
  </id_info>
  <brief_title>Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting</brief_title>
  <acronym>NEPAL</acronym>
  <official_title>Prospective Evaluation of Neurologic and Psychiatric Adverse Events of Rilpivirine, Elvitegravir, or Dolutegravir in a Real Life Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The frequency of neurological and psychiatric complaints for participants taking rilpivirine,
      elvitegravir, or dolutegravir reaches on average 20â€”30% during clinical trials. The inclusion
      and exclusion criteria for enrolling people living with HIV are at times so selective and the
      subsequent descriptions of minor or severe adverse events (AE's) so often imprecise and
      ambiguous that one cannot extrapolate these particular research results to practicing
      medicine. These adverse events negatively affect the patient's quality of life and ultimately
      his or her good adherence to treatments.

      This study aims at assessing the prevalence and at describing the neurological and
      psychiatric adverse events related to these drugs.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unfavourable opinion of ethical comittee for Amendment Nr 3
  </why_stopped>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with neurologic and/or psychiatric adverse events</measure>
    <time_frame>6 months after modification or initiation of a treatment with one of the following drugs: dolutegravir, elvitegravir ou la rilpivirine</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>exposition to the drugs</arm_group_label>
    <description>patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients non exposed to the drugs</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir</intervention_name>
    <description>chemical dosage ARV</description>
    <arm_group_label>exposition to the drugs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients with a prescription of rilpivirine, elvitegravir, or dolutegravir
        (modification or initiation of an antiretroviral treatment) and non exposed HIV patients,
        who don't take these drugs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  age &gt; 18

          -  treatment with rilpivirine, elvitegravir, or dolutegravir (for exposed patients)

          -  treatment with none of these drugs (for non exposed patients)

          -  capacity of reading French language

        Exclusion Criteria:

          -  drugs addiction (except for amyl nitriles (&quot;poppers&quot;) and cannabis)

          -  alcoholism

          -  co-infection with hepatitis C virus

          -  pregnant or breast feeding patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine MOULIGNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique A. de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

